Changfa Guo, MD, Husnain Kh. Haider, PhD, Winston S. N

Slides:

Advertisements

Similar presentations

In vitro tissue engineering of a cardiac graft using a degradable scaffold with an extracellular matrix–like topography Osamu Ishii, MD, Michael Shin,

Advertisements

Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium K.H Grinnemo, MD, A Månsson, MD, G Dellgren,

Tracking cardiac engraftment and distribution of implanted bone marrow cells: Comparing intra-aortic, intravenous, and intramyocardial delivery Shu-Hong.

Manuel J. Antunes, MD, PhD, DSc

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Mammalian Cardiac Regeneration After Fetal Myocardial Infarction Requires Cardiac Progenitor Cell Recruitment Myron Allukian, MD, Junwang Xu, PhD, Michael.

Tracking cardiac engraftment and distribution of implanted bone marrow cells: Comparing intra-aortic, intravenous, and intramyocardial delivery Shu-Hong.

Simvastatin attenuates cardiac isograft ischemia-reperfusion injury by down-regulating CC chemokine receptor-2 expression Rong Yin, MD, Jiaquan Zhu,

Association of CD14+ monocyte-derived progenitor cells with cardiac allograft vasculopathy Mohamed Salama, MD, PhD, Olena Andrukhova, PhD, Susanne Roedler,

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac.

Targeting survival pathways to create infarct-spanning bridges of human embryonic stem cell–derived cardiomyocytes Jun Luo, MD, PhD, Matthew S. Weaver,

Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium Yifu Zhou,

Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans Katharina Krenn, MD, Matthias Gmeiner, MD, PhD, Patrick Paulus, MD, Nezir.

The role of methylene blue in serotonin syndrome following cardiac transplantation: A case report and review of the literature Kendra J. Grubb, MD, Jamie.

Mechanical preconditioning enables electrophysiologic coupling of skeletal myoblast cells to myocardium Klaus Neef, PhD, Yeong-Hoon Choi, MD, Sureshkumar.

Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor Shafie Fazel, MD, MSc, Liwen.

Bone marrow–derived mononuclear cell transplantation improves myocardial recovery by enhancing cellular recruitment and differentiation at the infarction.

Volume 5, Issue 5, Pages (November 2015)

Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy Volker Ruppert, MD, Thomas.

Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic.

Changfa Guo, MD, Husnain Kh

Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects on myogenesis and angiogenesis Jiang-Yong Min, MD, Yu Chen, MD, Sohail.

Persistence of marrow stromal cells implanted into acutely infarcted myocardium: Observations in a xenotransplant model Derek J. MacDonald, MD, Jun Luo,

A novel vascularized patch enhances cell survival and modifies ventricular remodeling in a rat myocardial infarction model Qi Zhou, MD, PhD, Jian-Ye.

Myocardial regeneration for chronic heart failure: Not as easy as it sounds Richard A. Hopkins, MD The Journal of Thoracic and Cardiovascular Surgery

Homing of intravenously infused embryonic stem cell-derived cells to injured hearts after myocardial infarction Jiang-Yong Min, MD, Xuling Huang, MD,

Intrinsic cardiac stem cells are essential for regeneration

Preventing cardiac remodeling: The combination of cell-based therapy and cardiac support therapy preserves left ventricular function in rodent model of.

Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure Mark F. Berry, MD, Timothy.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Vascular endothelial growth factor transgene expression in cell-transplanted hearts Terrence M. Yau, MD, MSc, Guangming Li, MD, Richard D Weisel, MD,

A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted Jayan Nagendran, MD, Vikram.

Marrow Stromal Cells as Universal Donor Cells for Myocardial Regenerative Therapy: Their Unique Immune Tolerance Rony Atoui, MD, MS, Juan-Francisco Asenjo,

Myoblast Transplantation for Cardiac Repair: A Clinical Perspective

Injection of bone marrow mesenchymal stem cells in the borderline area of infarcted myocardium: Heart status and cell distribution Hao Zhang, MD, PhD,

Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation Yosuke Tanaka, MD, Tomomi Hasegawa, MD, PhD,

Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis Zhi-Qiang Luo, MD, Xing-Hai Hao,

Single-dose rosuvastatin ameliorates lung ischemia–reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage.

Preliminary experience with porcine intestinal submucosa (CorMatrix) for valve reconstruction in congenital heart disease: Histologic evaluation of explanted.

Improvement of cardiac function in the failing rat heart after transfer of skeletal myoblasts engineered to overexpress placental growth factor Matthias.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mammalian Cardiac Regeneration After Fetal Myocardial Infarction Requires Cardiac Progenitor Cell Recruitment Myron Allukian, MD, Junwang Xu, PhD, Michael.

Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model Yasuhiro.

It's not “just a shunt” but sometimes it should be…

Bartley P. Griffith, MD, FACS, FRCS

A first start for lung transplantation?

Robotic minimally invasive cell transplantation for heart failure

Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart Naosumi Sekiya, MD, Goro Matsumiya, MD, PhD, Shigeru.

Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep

Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium K.H Grinnemo, MD, A Månsson, MD, G Dellgren,

Association of electrostimulation with cell transplantation in ischemic heart disease Abdel Shafy, MD, Thomas Lavergne, MD, Christian Latremouille, MD,

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia Muhammad I. Niagara, MSc, Husnain.

Is endoluminal vacuum therapy “sponge worthy”?

Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model Hiroki Hata, MD, Goro Matsumiya, MD, PhD,

Regenerative therapy for hypoplastic left heart syndrome: First report of intraoperative intramyocardial injection of autologous umbilical-cord blood–derived.

Functional tricuspid pathology: To treat or not to treat

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Pavan Atluri, MD, Corinna M. Panlilio, BA, George P. Liao, MB, Eric E

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

The Robin Hood principle in the treatment of congenital heart disease: Taking technologic developments intended for adults and using it in kids Paul.

Why arch curvature affects arch resistance

Optimizing cardiac cell therapy: From processing to delivery

Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy Y.

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Marrow stromal cells for cellular cardiomyoplasty: Feasibility and potential clinical advantages Jih-Shiuan Wang, MDa,b, Dominique Shum-Tim, MDa, Jacques.

Tina Khanam, B.Sc., Geoffrey Burnstock, Ph.D., D.Sc.

Presentation transcript:

Myoblast-based cardiac repair: Xenomyoblast versus allomyoblast transplantation Changfa Guo, MD, Husnain Kh. Haider, PhD, Winston S.N. Shim, PhD, Ru-San Tan, MBBS, Lei Ye, MD, PhD, Shujia Jiang, MD, Peter K. Law, PhD, Philip Wong, MBBS, Eugene K.W. Sim, FRCS The Journal of Thoracic and Cardiovascular Surgery Volume 134, Issue 5, Pages 1332-1339.e2 (November 2007) DOI: 10.1016/j.jtcvs.2007.07.025 Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Immunostaining and observation of time of infiltration of macrophages (A and B), CD8+ cells (C and D), and CD4+ cells (E and F) into the cell injection site (magnification ×400). *Significantly increased numbers of infiltrating cells (including macrophages, CD4+ cells, and CD8+ cells) compared with those of groups 1 or 2 (groups 3 and 5 vs group 1; groups 4 and 6 vs group 2, P < .01). #After cyclosporine treatment, the infiltrating cells (including macrophages, CD4+ cells, and CD8+ cells) significantly decreased compared with those in the groups not receiving cyclosporine treatment (group 4 vs group 3 and group 6 vs group 5, P < .01). The Journal of Thoracic and Cardiovascular Surgery 2007 134, 1332-1339.e2DOI: (10.1016/j.jtcvs.2007.07.025) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Echocardiographic analysis showed improved heart function after skeletal myoblast transplantation. There was no significant difference in baseline heart performance (ejection fraction [EF] and fractional shortening [FS]) among the different groups of animals. Within groups, significant improvement in EF and FS was observed after skeletal myoblast transplantation (groups 3–6) compared with baseline values (P < .01), whereas there was no functional improvement in the DMEM-treated groups (groups 1 and 2). Between-group analyses: *Significant improvement of EF/FS compared with that seen in control group 1 (comparison among groups not receiving cyclosporine treatment). †Significant improvement of EF/FS compared with control group 2 (comparison among cyclosporine-treated groups, P < .01). In the EF arm (A), with cyclosporine treatment, EF increased to a significant level compared with that seen in the groups not receiving cyclosporine treatment (group 4 vs group 3 and group 6 vs group 5, P < .05). No significant improvement was observed in allogeneic groups compared with that of xenogeneic groups (group 5 vs group 3 and group 6 vs group 4). In the FS arm (B) no significant difference was observed in the skeletal myoblast transplantation groups (groups 3-6) after cell therapy. The Journal of Thoracic and Cardiovascular Surgery 2007 134, 1332-1339.e2DOI: (10.1016/j.jtcvs.2007.07.025) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Immunostaining and flow cytometric assay of skeletal myoblasts for desmin and 4′,6′-diamidino-2-phenylindole hydrochloride and lac-z labeling efficiency. A1, Green fluorescent cytoplasm showing desmin-positive skeletal myoblasts. A2, Human skeletal myoblasts were 98.89% pure (blue curve) for desmin expression when gated for control at 1.02% (red curve) by means of flow cytometric assay. B1, Desmin-positive rat skeletal myoblasts. B2, Rat skeletal myoblasts were 75.35% pure (blue) for desmin expression when gated for control at 1.02% (red) by means of flow cytometric assay. C1, 4′,6′-Diamidino-2-phenylindole hydrochloride–labeled skeletal myoblasts (blue nuclei). C2, Merged image of panel C1 and phase-contrast image to show total number of cells. D, Lac-z–positive cells with green nuclei. (Original magnification: 200×). The Journal of Thoracic and Cardiovascular Surgery 2007 134, 1332-1339.e2DOI: (10.1016/j.jtcvs.2007.07.025) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure E2 Myoblast survival and differentiation after transplantation. A, 4′,6′-Diamidino-2-phenylindole hydrochloride–labeled skeletal myoblasts 7 days after transplantation. Note the presence of cells at the injection site without orientation. B, 4′,6′-Diamidino-2-phenylindole hydrochloride–labeled skeletal myoblasts 28 days after transplantation showed typically aligned orientation, which followed host muscle architecture. C, Hematoxylin and eosin staining to show the myocardium of continuous section from panel B. D, Myosin heavy chain (slow isoform) immunostaining counterstained with hematoxylin to show myoblast differentiation and (E). F, Myosin heavy chain (fast isoform) immunostaining counterstained with hematoxylin. G, Myoblast survival confirmed by lac-z staining (green nuclei) counterstained with hematoxylin. (Original magnifications: A-D, 100×; E-F, 800×; G, 400×). The Journal of Thoracic and Cardiovascular Surgery 2007 134, 1332-1339.e2DOI: (10.1016/j.jtcvs.2007.07.025) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions